Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameViva Biotech
Stock Code01873
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities經營基於結構的新藥發現技術平台,為全球生物科技及製藥客戶的臨床前階段創新藥物開發提供藥物發現服務,涵蓋靶標蛋白表達與結構研究、藥物篩選、先導化合物優化至確定臨床候選化合物。
Listing Date2019-05-09
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市浦東新區張江高科技園區愛迪生路334號
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitevivabiotech.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 4.41 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2019-04-25 to 2019-04-30
Global Offering Shares345,000,000 shares
HK Public Offer Shares (Initial)34,500,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)310,500,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,500,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share23.1%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,521,450,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 3.27B
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +197%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201620172018
Revenue 96,492148,245210,033
Cost of sales -42,349-62,056-104,576
Gross profit 54,14386,189105,457
Other income and gains, net 7,0886,4124,671
Selling and distribution expenses -1,392-2,017-3,925
Administrative expenses -12,827-15,228-25,576
Net finance costs -203-853-557
Share of associates and JVs -3,403-4,112-3,246
Profit before tax 28,42086,811105,861
Income tax expense -3,947-10,551-15,311
Profit for the year 24,47376,26090,550
Balance Sheet
Item 201620172018
Cash and cash equivalents 13,42529,766155,554
Trade and bills receivables 24,06436,87568,410
Inventories 1,0133,3234,900
Total current assets 65,16483,447241,170
Total assets 101,821202,402529,339
Total current liabilities 16,32036,99142,462
Total liabilities 25,31949,640277,897
Total equity 76,502152,762251,442
Interest-bearing borrowings 3,50614,9452,362
Cash Flow Statement
Item 201620172018
Net cash from operating activities 21,11827,89112,110
Net cash from investing activities -19,589-9,762-69,949
Net cash from financing activities -741-849179,479
Net increase in cash 78817,280121,640
Depreciation of PP&E 3,7825,5019,548
Purchase of PP&E -7,341-18,923-46,903
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 4.42
First Day OpenHK$ 4.51
First Day Change0.23%
First Day Volume155638000.0
First Day Turnover704407000.0
Use of Proceeds
1、約30%或411.8百萬港元將用于擴大EFS模式,將更多前景可觀的中國及海外生物科技初創公司加入我們的孵化投資企業組合; 2、約30%或411.8百萬港元將用于建立商業及研究制作能力及生物CMO及化學CMO的能力; 3、約10%或137.3百萬港元將用于按擴充計劃購置實驗室設備及物料; 4、約10%或137.3百萬港元將用于招聘、培訓及保留生物及化學藥物研發人員; 5、約10%或137.3百萬港元將用于擴充CMO業務,可能包括收購新技術、業務或服務,及╱或與第三方建立戰略聯盟; 6、約10%或137.3百萬港元將用作我們的一般公司及營運資金。

Underwriting Syndicate

Sole Sponsor (1)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Overall Coordinators (3)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 Nomura International (Hong Kong) Limited CE AAF742
Joint Bookrunners (6)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 Nomura International (Hong Kong) Limited CE AAF742 BOCI ASIA LIMITED CE AET863 China Renaissance Securities (Hong Kong) Limited CE AZX839 海通国际证券有限公司 CE AAF806
Joint Lead Managers (8)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321 Nomura International (Hong Kong) Limited CE AAF742 BOCI ASIA LIMITED CE AET863 China Renaissance Securities (Hong Kong) Limited CE AZX839 海通国际证券有限公司 CE AAF806 Daiwa Capital Markets Hong Kong Limited CE AAB639 FIRST SHANGHAI SECURITIES LIMITED CE ABV488

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Gaotejia Investment Management Co., Ltd 94,111,605 HKD — 6.19% — 6 months 2019-11-09
2 深圳市高特佳睿宝投资合伙企业(有限合伙) 141,168,510 HKD — 9.28% — 6 months 2019-11-09
3 中国医药投资有限公司 116,790,030 HKD — 7.68% — 6 months 2019-11-09

Directors & Management

PositionChinese nameEnglish Name
Chairman毛晨—
Company Secretary費曉玉、周慶齡—
No director data available.

Major Shareholders

Major Shareholders & Holdings毛先生持股23.46%、毛女士持股21.11%、吳炯先生持股17.05%、Zhang and Sons持股10.63%、Fenghe Harvest持股10.32%、華先生持股8.26%
About this page

This page shows Viva Biotech (01873) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect